Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.79Last Year’s EPS
-0.39Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -9.83%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call was largely positive with the successful launch of Attruby driving significant revenue and the strong progress of the pipeline. While there were increased SG&A expenses due to the commercial rollout, the overall impact was minimal compared to the positive developments.Company Guidance
During the Q1 2025 earnings call, BridgeBio provided guidance on several key metrics. The company reported $36.7 million in revenue from the launch of Attruby, emphasizing its clinical efficacy and cost-effectiveness. Attruby demonstrated a 42% relative risk reduction in cardiovascular hospitalization and mortality at 30 months, including a 50% reduction in cardiovascular hospitalization. BridgeBio's net present value (NPV) increased by 9% due to higher-than-expected revenue and early enrollment in trials, despite minor NPV drags from tariffs. The company is preparing for three Phase 3 readouts in the next year, expecting these developments to significantly impact their pipeline. BridgeBio maintains a focus on maximizing quality-adjusted life years for patients, striving for programs that are first-in-class or best-in-class, and ensuring each program is NPV positive.Successful Attruby Launch
Attruby generated $36.7 million in revenue in its first quarter, with 2,072 unique patients receiving a prescription and 756 unique healthcare providers writing at least one prescription. The product demonstrated a 42% relative risk reduction in cardiovascular hospitalization and mortality at 30 months, including a 50% reduction in cardiovascular hospitalization.
Pipeline Progress
BridgeBio's pipeline includes three Phase 3 readouts expected in the next year, with trials in limb-girdle muscular dystrophy 2I, achondroplasia, and ADH1 on track. Additionally, the hypochondroplasia trial enrolled its first patient quickly, and positive POC data for encaleret in hypoparathyroidism was announced.
Financial Performance
Total revenues for Q1 2025 were $116.6 million, exceeding expectations. The company's NPV increased by 9% due to various factors, including better-than-anticipated revenue from Attruby and a successful convertible offering.
Strong Market Positioning
Attruby is positioned as the most cost-effective therapy in the ATTR-CM market, being 10% less expensive than tafamidis and 50% less expensive than vutrisiran. It also offers a free trial program for all patients and lifetime free drug for trial participants.
BBIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BBIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | $36.42 | $38.36 | +5.33% |
Feb 20, 2025 | $36.29 | $36.80 | +1.41% |
Nov 12, 2024 | $26.12 | $24.62 | -5.74% |
Aug 01, 2024 | $25.95 | $26.18 | +0.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BridgeBio Pharma Inc (BBIO) report earnings?
BridgeBio Pharma Inc (BBIO) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is BridgeBio Pharma Inc (BBIO) earnings time?
BridgeBio Pharma Inc (BBIO) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BBIO EPS forecast?
BBIO EPS forecast for the fiscal quarter 2025 (Q2) is -0.79.